Biomoda Inc. (fka BMODQ)

[dgras0007]

"This is a significant milestone for our CyPath® diagnostic test," Cousins said. "Now that enrollment and collection are complete, the study team is evaluating data in preparation for publishing results when analysis is complete. We expect the results from this single-blind, non-randomized clinical trial to lead to the launch of the Phase III pivotal trial."

I'm assuming that the word "analysis" means analysis of the data, not the samples since he says that the study team is "evaluating the data in prep. for publishing"